leisure time -WSS

leisure time

author：knowledge 2025-09-03 15:17:52 - browse：9

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Chinese researcher claims birth of first gene

focus

WSS

Mirador, a new biotech startup, launches with $400 million

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Merck drug for rare lung condition set for approval in U.S.

What Kate Middleton's cancer revelation might teach the world

Roche subsidiary Foundation Medicine opens new headquarters

Mirador, a new biotech startup, launches with $400 million

knowledge

leisure time

focus

Guidelines to prevent youth baseball injuries need more muscle

This gene therapy has record $4.25 million price. It's saved children.

Novavax promises a turnaround & Lilly roils the obesity market

Patient advocates debate FDA's accelerated approval process

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Abortion pill case raises question: who can sue the FDA?

Walensky prepares to leave CDC — and Congress — behind

Covid vaccine financial winners and losers, from Pfizer to Novavax

hotspot

Biotech investment managers search for lucrative opportunities

Steward Health Care expansion into Malta flopped

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Eliminate the waiting period for sterilization covered by Medicaid

Decaf coffee targeted by food safety group under obscure FDA rule

Medical devices makers are asking for forgiveness, not permission

explore

focus

entertainment

hotspot